Lytix Biopharma's licensing partner Verrica Pharmaceuticals Inc (“Verrica”) reported lesion clearance data from Part 1 of an ongoing Phase II study of VP-315 (formerly known as LTX-315) for the treatment of basal cell carcinoma (BCC). Verrica has an exclusive worldwide license agreement with Lytix to develop and commercialize LTX-315 for dermatologic oncology indications and is currently performing a clinical Phase II study in patients with BCC.

The results were orally presented at the 2023 American Academy of Dermatology Innovation Academy meeting, August 10-13, in Tampa, Florida, and the data stirs attention.

Among the articles, check:

• TV2.no (in Norwegian)
• FA.no (in Norwegian)
• Nordlys.no (in Norwegian and behind paywall)
• MedWatch (behind paywall)
• Scrip